The emerging role of immunotherapy for the treatment of early and advanced breast cancer

Bookmark and Share
Published: 18 Dec 2019
Views: 527
Dr Rita Nanda - UChicago Medicine, Chicago, USA

Dr Rita Nanda speaks to ecancer at the 2019 San Antonio Breast Cancer Symposium about the new updates in immunotherapy for the treatment of triple-negative breast cancer.

She mentions the approval of atezolizumab and nab-paclitaxel for the treatment of metastatic, triple-negative breast cancer as a major highlight in this area, along with emerging data focusing on new combination strategies.

Dr Nanda discusses the related toxicities, PDL-1 testing and the optimistic future for immunotherapy - especially in early-stage disease.